TY - JOUR T1 - Update on the OMERACT Magnetic Resonance Imaging Task Force: Research and Future Directions JF - The Journal of Rheumatology JO - J Rheumatol SP - 383 LP - 385 DO - 10.3899/jrheum.131085 VL - 41 IS - 2 AU - Philip G. Conaghan AU - Fiona M. McQueen AU - Paul Bird AU - Charles Peterfy AU - Espen Haavardsholm AU - Frédérique Gandjbakhch AU - Iris Eshed AU - Ida K. Haugen AU - Siri Lillegraven AU - Uffe Møller Døhn AU - Bo Ejbjerg AU - Violaine Foltz AU - Laura Coates AU - Pernille Bøyesen AU - Kay-Geert Hermann AU - Jane Freeston AU - Marissa Lassere AU - Philip O’Connor AU - Paul Emery AU - Harry Genant AU - Mikkel Østergaard Y1 - 2014/02/01 UR - http://www.jrheum.org/content/41/2/383.abstract N2 - Magnetic resonance imaging (MRI) provides an important biomarker across a range of rheumatological diseases. At the Outcome Measures in Rheumatology (OMERACT) 11 meeting, the MRI task force continued its work of developing and improving the use of MRI outcomes for use in clinical trials. The breadth of pathology in the Rheumatoid Arthritis MRI Score has been strengthened with further work on the development of a joint space narrowing score, and a series of exercises presented at OMERACT 11 demonstrated good reliability and construct validity for this assessment. Understanding the importance of residual inflammation after RA treatment remains a major focus of the group’s work. Analyses were presented on defining the level of synovitis (using MRI scores of a single hand) that would predict absence of erosion progression. The development of the OMERACT Hand Osteoarthritis MRI score has continued with substantial work presented on its iterative development, including pathology definition, scaling, and subsequent reliability of the score. Optimizing the role of MRI as a robust biomarker and surrogate outcome remains a priority for this group. ER -